<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464695</url>
  </required_header>
  <id_info>
    <org_study_id>O2MATIC-COPD</org_study_id>
    <nct_id>NCT03464695</nct_id>
  </id_info>
  <brief_title>Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD</brief_title>
  <acronym>O2MATIC</acronym>
  <official_title>Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovation Fund Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine if automated oxygen delivery with O2matic is better than
      manually controlled oxygen therapy for patients admitted to hospital with an exacerbation in
      Chronic Obstructive Pulmonary Disease (COPD).

      O2matic is a closed -loop system based on continuous non-invasive measurement of pulse and
      oxygen-saturation that is processed in an algorithm that controls the flow of oxygen to the
      patient.

      The primary hypothesis is that O2matic increases time within acceptable oxygen-saturation
      interval and reduces time with hypoxia and hyperoxia. Secondary hypotheses are that O2matic
      improves patient's sense of safety compared to manual control, reduces nurse's workload,
      reduces admission time and reduces time spent with oxygen therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Closed-loop control of oxygen therapy is described in the literature used for preterm
      infants, trauma patients, medical emergency use and patients with COPD. For the latter,
      closed-loop therapy has been used for patients admitted to hospital with an exacerbation, for
      domiciliary oxygen use and during exercise. O2matic is a closed-loop system that is based on
      continuous and non-invasive measurement of pulse, oxygen-saturation and respiratory
      frequency. The algorithm in O2matic controls oxygen delivery with the aim of keeping the
      saturation within the desired interval, which could be 88-92 % for COPD-patients in
      accordance with international guidelines on this topic. Saturation interval can be set for
      the individual patients, as can the range of acceptable oxygen-flow. If saturation or
      oxygen-flow can't be maintained within the desired intervals an alarm will sound.

      All studies on closed-loop systems have shown that this method is better than manually
      control by nurse to maintain saturation within the desired interval. Furthermore, some
      studies have indicated that closed-loop has the possibility to reduce admission time and to
      reduce time spent with oxygen therapy, due to more efficient and fast withdrawal from oxygen
      supplementation.

      In the present study O2matic will be tested in a randomized, controlled, un-blinded setting
      versus manual control, for patients admitted with an exacerbation in COPD, and in need of
      supplemental oxygen. For the whole duration of the admission patients will either have oxygen
      controlled with O2matic or manually by nursing staff. All patients will have continuous
      logging of pulse, oxygen-saturation and oxygen-flow with O2matic, but only in the O2matic
      active group, the algorithm will control oxygen-delivery.

      In Phase one of the O2matic trial the primary hypothesis will be tested, which is that
      O2matic is better than manual control for maintaining oxygen-saturation within the desired
      interval and reducing time with unintended hypoxia and hyperoxia. For this purpose 15
      patients will be included in the active arm and 15 patients in the control arm. In Phase two
      of the O2matic trial the secondary hypotheses will be tested, which are that O2matic will
      increase patient's sense of safety compared to manual control and that O2matic will reduce
      admission time and time spent with oxygen-therapy compared to manual control. In Phase two of
      the study 150 patients will be included in each arm.

      No safety issues has been reported in the literature. Before use O2matic will be approved by
      The Danish Medicines Agency, The Ethics Committee in the Capital Region of Denmark and by the
      regional Data Protection Board. The study will be conducted according to GCP standards with
      independent monitoring. All adverse events and serious adverse events will be monitored and
      serious adverse events will be reported to Danish Medicines Agency. A follow-up on the study
      will look at mortality and readmissions within 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time within SpO2-interval</measure>
    <time_frame>From inclusion to hospital discharge or dropout, on average 5 days</time_frame>
    <description>Fraction of time where SpO2 is kept within desired interval (e.g. 88-92 %) relative to time with SpO2-signal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time with hypoxia</measure>
    <time_frame>From inclusion to hospital discharge or dropout, on average 5 days</time_frame>
    <description>Fraction of time where SpO2 is below target interval relative to time with SpO2 signal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time with hyperoxia</measure>
    <time_frame>From inclusion to hospital discharge or dropout, on average 5 days</time_frame>
    <description>Fraction of time where SpO2 is above target interval relative to time with SpO2 signal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Admission time</measure>
    <time_frame>From inclusion to hospital discharge, on average 5 days</time_frame>
    <description>Time from admission to discharge or condition respiratory stable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen delivery time</measure>
    <time_frame>From inclusion to hospital discharge or dropout, on average 5 days</time_frame>
    <description>Time from randomization to oxygen-delivery is completely withdrawn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nurse time consumption</measure>
    <time_frame>From inclusion to hospital discharge or dropout, on average 5 days</time_frame>
    <description>Time used by nurses to monitor and control oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient comfort and safety</measure>
    <time_frame>From inclusion to hospital discharge or dropout, on average 5 days</time_frame>
    <description>Patient's perception of safety and comfort measured on visual analog scales</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COPD Exacerbation</condition>
  <condition>Hypoxia</condition>
  <condition>Hyperoxia</condition>
  <condition>Respiratory Failure</condition>
  <condition>Respiratory Insufficiency</condition>
  <condition>Copd Exacerbation Acute</condition>
  <arm_group>
    <arm_group_label>O2matic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>O2matic</intervention_name>
    <description>Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.</description>
    <arm_group_label>O2matic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD verified by FEV1/FVC &lt; 0,70

          -  Admission due to exacerbation in COPD

          -  COPD exacerbation and pneumonia can be included

          -  Duration of admission &gt; 48 hours

          -  Need for oxygen supplementation on day 2 (SpO2 &lt;= 88 % without O2 suppl.)

          -  Cognitively able to participate in the study

          -  Willing to participate and give informed consent.

        Exclusion Criteria:

          -  Need or anticipated need for mechanical ventilation (except intermittent CPAP)

          -  Major co-morbidities (cancer, heart disease, thromboembolic disease, uncontrolled
             diabetes)

          -  Asthma or other respiratory condition requiring higher SpO2 than normal for COPD-
             patients

          -  Pregnancy

          -  Acute thromboembolic disease (&lt; 2 weeks)

          -  Cognitive barriers for participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¸rgen Vestbo, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Manchester University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ejvind Frausing Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital, Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ejvind Frausing Hansen, MD</last_name>
    <phone>+45 3862 3233</phone>
    <email>ejvind.frausing.hansen@regionh.dk</email>
  </overall_contact>
  <results_reference>
    <citation>Claure N, Bancalari E. Closed-loop control of inspired oxygen in premature infants. Semin Fetal Neonatal Med. 2015 Jun;20(3):198-204. doi: 10.1016/j.siny.2015.02.003. Epub 2015 Mar 12. Review.</citation>
    <PMID>25773271</PMID>
  </results_reference>
  <results_reference>
    <citation>Johannigman JA, Branson R, Lecroy D, Beck G. Autonomous control of inspired oxygen concentration during mechanical ventilation of the critically injured trauma patient. J Trauma. 2009 Feb;66(2):386-92. doi: 10.1097/TA.0b013e318197a4bb.</citation>
    <PMID>19204511</PMID>
  </results_reference>
  <results_reference>
    <citation>L'Her E, Dias P, Gouillou M, Riou A, Souquiere L, Paleiron N, Archambault P, Bouchard PA, Lellouche F. Automatic versus manual oxygen administration in the emergency department. Eur Respir J. 2017 Jul 20;50(1). pii: 1602552. doi: 10.1183/13993003.02552-2016. Print 2017 Jul.</citation>
    <PMID>28729473</PMID>
  </results_reference>
  <results_reference>
    <citation>Lellouche F, Bouchard PA, Roberge M, Simard S, L'Her E, Maltais F, Lacasse Y. Automated oxygen titration and weaning with FreeO2 in patients with acute exacerbation of COPD: a pilot randomized trial. Int J Chron Obstruct Pulmon Dis. 2016 Aug 24;11:1983-90. doi: 10.2147/COPD.S112820. eCollection 2016.</citation>
    <PMID>27601891</PMID>
  </results_reference>
  <results_reference>
    <citation>Lellouche F, L'Her E, Bouchard PA, Brouillard C, Maltais F. Automatic Oxygen Titration During Walking in Subjects With COPD: A Randomized Crossover Controlled Study. Respir Care. 2016 Nov;61(11):1456-1464. Epub 2016 Oct 18.</citation>
    <PMID>27794080</PMID>
  </results_reference>
  <results_reference>
    <citation>Rice KL, Schmidt MF, Buan JS, Lebahn F, Schwarzock TK. AccuO2 oximetry-driven oxygen-conserving device versus fixed-dose oxygen devices in stable COPD patients. Respir Care. 2011 Dec;56(12):1901-5.</citation>
    <PMID>22288082</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Ejvind Frausing Hansen</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>closed-loop</keyword>
  <keyword>oxygen treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

